M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$54bndisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Mar 2026 | JSR Life Sciences chromatography business | JSR Life Sciences | MERCK KGaA | Asset sale | Completed | – | Life Sciences+1 | William Blair |
| Feb 2026 | Bruder Consulting & Venture Group | – | Dark Horse Consulting Group | Acquisition | Completed | – | Accounting, legal and consulting+1 | Goodwin (sell-side)Edgemont Partners (sell-side) |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Announced | – | Pharma Services+2 | Goodwin (buy-side) |
| Feb 2026 | Dutscher Group | – | Vivo Capital | Acquisition | Announced | – | Life Sciences+1 | Sidley Austin (buy-side)Mayer Brown (buy-side) |
| Jan 2026 | Ganymede | – | Apprentice.io | Acquisition | Announced | – | Software+1 | Cooley (buy-side) |
| Jan 2026 | StarLIMS | – | Turn/River Capital | Stake | Announced | – | Software+2 | |
| Jan 2026 | Cannatrek | – | Little Green Pharma | Scheme | Completed | – | Healthcare+1 | K&L Gates (sell-side)Intrinsic Partners (sell-side)RSM (sell-side)Hamilton Locke (buy-side)Canaccord Genuity (buy-side) |
| Jan 2026 | Verana Health | – | – | Merger | Announced | – | Healthcare Software+2 | BofA Securities (sell-side)Wilson Sonsini Goodrich & Rosati (buy-side) |
| Jan 2026 | Aktana | – | PharmaForceIQ | Asset sale | Announced | – | Healthcare Software+2 | Canaccord Genuity |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Jan 2026 | BioRender | – | Dimension Capital | Stake | Announced | 900.0 | Software+2 | Sidley Austin (sell-side) |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Dec 2025 | Freenome Holdings | – | Perceptive Capital Solutions Corp | Merger | Completed | 725.0 | Diagnostics+2 | TD Securities (sell-side)Guggenheim Securities (sell-side)BTIG (sell-side)Goodwin (sell-side)Greenberg Traurig (sell-side)Richards, Layton & Finger (sell-side)H.C. Wainwright & Co. (sell-side)Jefferies (buy-side)Leerink Partners (buy-side)Cooley (buy-side)Ropes & Gray (buy-side)Maples Group (buy-side)Ogier (buy-side)Scalar (buy-side) |
| Oct 2025 | Sedarex | – | Biotron | Acquisition | Completed | 1.0 | Healthcare+1 | Peak Asset Management (buy-side) |
| Oct 2025 | SWK Holdings | – | Runway Growth Finance Corp. | Acquisition | Completed | 249.0 | Financial Services+1 | Keefe, Bruyette & Woods (sell-side)Goodwin (sell-side)Kroll (sell-side)Simpson Thacher & Bartlett (buy-side)Dechert (buy-side) |
| Aug 2025 | DBG Global Enterprises | – | BDT & MSD Partners | Stake | Announced | 1,039.4 | Healthcare+1 | MinterEllison (sell-side) |
| Aug 2025 | DBG Health | – | BDT & MSD Partners | Stake | Completed | 1,039.4 | Healthcare+1 | MinterEllison (sell-side)Allens (buy-side)Sidley Austin (buy-side) |
| Jul 2025 | BD Biosciences & Diagnostic Solutions business | Becton, Dickinson and Company | Waters | Asset sale | Completed | 18,800.0 | Life Sciences+2 | Citi (sell-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Barclays (buy-side)Kirkland & Ellis (buy-side) |
| Jun 2025 | InVetro | – | Animalcare Group | Stake | Announced | – | Healthcare+1 | Squire Patton Boggs (buy-side) |
| Feb 2025 | Mayne Pharma Group | – | Cosette Pharmaceuticals | Scheme | Withdrawn | 417.9 | Healthcare+1 | Jefferies (sell-side)Gilbert + Tobin (sell-side)Arnold & Porter (sell-side)Davis Wright Tremaine (sell-side)EY (sell-side)Deloitte (sell-side)Santander (buy-side)UBS (buy-side)Corrs Chambers Westgarth (buy-side)Ropes & Gray (buy-side) |
| Feb 2025 | AdvanCell | – | SV Health Investors | Stake | Completed | – | Healthcare+1 | Johnson Winter Slattery (buy-side)Honigman (buy-side) |
| Jan 2025 | ImaginAb therapeutic candidates, biologics technology platform and research facility | ImaginAb | Telix Pharmaceuticals | Asset sale | Completed | 45.0 | Healthcare+1 | Jefferies (sell-side)Stifel (sell-side) |
| Dec 2024 | Randlab Group | – | Animalcare Group | Acquisition | Completed | 74.3 | Healthcare+1 | Squire Patton Boggs (buy-side)Pitcher Partners (buy-side) |
| Apr 2024 | Model N | – | Vista Equity Partners | Acquisition | Completed | 1,250.0 | Vertical SaaS+1 | Jefferies (sell-side)Fenwick & West (sell-side)Kirkland & Ellis (buy-side)William Blair (buy-side) |
| – | Northpharm | – | Fortitude | Acquisition | Announced | – | Healthcare+1 | KPMG (sell-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.